Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart

International Immunopharmacology

Volumn 5, Issue 2, 2005, Pages 381-391

  Hong, Ting Ting ^a   White, Andrew J ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Complement; Dermatan 4, 6 disulfate; GAGs; Intimatan; LVDP; LVEDP

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; DERMATAN DISULFATE; GLYCOSAMINOGLYCAN; INTIMATAN; TROPONIN I; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL VIABILITY; COMPLEMENT SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EXPOSURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PERFUSION; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RABBIT; TISSUE SLICE;

ANIMALS; ANTICOAGULANTS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DERMATAN SULFATE; HEART; HUMANS; MYOCARDIAL REPERFUSION INJURY; PLASMA; RABBITS; VENTRICULAR FUNCTION, LEFT;

EID: 12344276758     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.10.013     Document Type: Article

References (43)

1. W. Hollander, M.A. Colombo, B. Kirkpatrick, and J. Paddock Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin Atherosclerosis 34 1979 391 405
2. R. Vlaicu, F. Niculescu, H.G. Rus, and A. Cristea Immune deposits in human aortic atherosclerotic wall Med. Interne 21 1983 3 8
3. G.K. Hansson, J. Holm, and J.G. Kral Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions Acta Pathol. Microbiol. Immunol. Scand. [A] 92 1984 429 435
4. R. Vlaicu, F. Niculescu, H.G. Rus, and A. Cristea Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque Atherosclerosis 57 1985 163 177
5. H.G. Rus, F. Niculescu, E. Constantinescu, A. Cristea, and R. Vlaicu Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque Atherosclerosis 61 1986 35 42
6. A. Agostoni, M. Gardinali, D. Frangi, C. Cafaro, L. Conciato, and G. Sponzilli Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator Circulation 1994 2666 2670
7. D. Frangi, M. Gardinali, L. Conciato, C. Cafaro, L. Pozzoni, and A. Agostoni Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase Circulation 1994 76 80
8. J.H. Hill, and P.A. Ward The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats J. Exp. Med. 133 1971 885 900
9. R.D. Rossen, J.L. Swain, L.H. Michael, S. Weakley, E. Giannini, and M.L. Entman Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury Circ. Res. 57 1985 119 130
10. M.H. Crawford, F.L. Grover, W.P. Kolb, C.A. McMahan, and R.A. O'Rourke Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury Circulation 78 1988 1449 1458
11. R.D. Rossen, L.H. Michael, A. Kagiyama, H.E. Savage, and G. Hanson Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1q in vivo Circ. Res. 62 1988 572 584
12. D. Mathey, J. Schofer, H.J. Schafer, T. Hamdoch, H.C. Joachim, and A. Ritgen Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion Eur. Heart J. 15 1994 418 423
13. K. Yasojima, K.S. Kilgore, R.A. Washington, B.R. Lucchesi, and P.L. McGeer Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion Circ. Res. 82 1998 1224 1230
14. B.R. Lucchesi, and E.J. Tanhehco Therapeutic potential of complement inhibitors in myocardial ischaemia Expert Opin. Investig. Drugs 9 2000 975 991
15. G.S. Friedrichs, K.S. Kilgore, P.J. Manley, M.R. Gralinski, and B.R. Lucchesi Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart Circ. Res. 75 1994 701 710
16. K.S. Kilgore, K.B. Naylor, E.J. Tanhehco, J.L. Park, E.A. Booth, and R.A. Washington The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart J. Pharmacol. Exp. Ther. 285 1998 987 994
17. E. Raepple, H.U. Hill, and M. Loos Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement: I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4 Immunochemistry 13 1976 251 255
18. J.M. Weiler, R.E. Edens, R.J. Linhardt, and D.P. Kapelanski Heparin and modified heparin inhibit complement activation in vivo J. Immunol. 148 1992 3210 3215
19. M.D. Sharath, Z.M. Merchant, Y.S. Kim, K.G. Rice, R.J. Linhardt, and J.M. Weiler Small heparin fragments regulate the amplification pathway of complement Immunopharmacology 9 1985 73 80
20. S. Meri, and M.K. Pangburn Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H Proc. Natl. Acad. Sci. U. S. A. 87 1990 3982 3986
21. M.R. Buchanan, and S.J. Brister Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist Thromb. Res. 99 2000 603 612
22. R.M. Maaroufi, J. Tapon-Bretaudiere, J. Mardiguian, C. Sternberg, M.D. Dautzenberg, and A.M. Fischer Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives Thromb. Res. 59 1990 749 758
23. M.R. Buchanan, G.A. Maclean, and S.J. Brister Selective and sustained inhibition of surface-bound thrombin activity by intimatan/heparin cofactor II and its relevance to assessing systemic anticoagulation in vivo, ex vivo and in vitro Thromb. Haemost. 86 2001 909 913
24. J.K. Hennan, T.T. Hong, A.K. Shergill, E.M. Driscoll, A.D. Cardin, and B.R. Lucchesi Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury J. Pharmacol. Exp. Ther. 301 2002 1151 1156
25. Van Gorp CLBS, Buchanan MR. Dermatan disulfate, an inhibitor of thrombin generation and complement activation. 1997: USA.
26. S.C. Black, M.R. Gralinski, G.S. Friedrichs, K.S. Kilgore, E.M. Driscoll, and B.R. Lucchesi Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury Cardiovasc. Res. 29 1995 629 636
27. J.W. Homeister, P. Satoh, and B.R. Lucchesi Effects of complement activation in the isolated heart. Role of the terminal complement components Circ. Res. 71 1992 303 319
28. J.W. Homeister, P.S. Satoh, K.S. Kilgore, and B.R. Lucchesi Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart J. Immunol. 150 1993 1055 1064
29. J.L. Park, K.S. Kilgore, K.B. Naylor, E.A. Booth, K.L. Murphy, and B.R. Lucchesi N-Acetylheparin pretreatment reduces infarct size in the rabbit Pharmacology 58 1999 120 131
30. J.A. Fernandez, J. Petaja, and J.H. Griffin Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C Thromb. Haemost. 82 1999 1462 1468
31. J.C.S.M. Papadimitriou, and G.M. Hansch Mechanism of complement mediated membrane damage W.J. Mergner R.T. Jones B.F. Trump Cell Death, Mechanisms of Acute and Lethal Cell Injury 1990 Field and Wood New York 75 78
32. TA. Platts-Mills, and K. Ishizaka Activation of the alternate pathway of human complements by rabbit cells J. Immunol. 113 1974 348 358
33. W. Seeger, R. Hartmann, H. Neuhoff, and S. Bhakdi Local complement activation, thromboxane-mediated vasoconstriction, and vascular leakage in isolated lungs. Role of the terminal complement sequence Am. Rev. Respir. Dis. 139 1989 88 99
34. B. Morgan Effects of the membrane attack complex of complement on nucleated cells P. CJ Membrane defenses against attack by complement and perforins 1992 Springer-Verlag 115 140
35. J.C. Papadimitriou, C.B. Drachenberg, M.L. Shin, and B.F. Trump Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury Virchows Arch. 424 1994 677 685
36. J. Schaper, and W. Schaper Reperfusion of ischemic myocardium: ultrastructural and histochemical aspects J. Am. Coll. Cardiol. 1 1983 1037 1046
37. R.J. Linhardt, K.G. Rice, Y.S. Kim, J.D. Engelken, and J.M. Weiler Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro J. Biol. Chem. 263 1988 13090 13096
38. M.A. Blajchman, and A.H. Ozge-Anwar The role of the complement system in hemostasis Prog. Hematol. 14 1986 149 182
39. RJ. Johnson Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance Nephrol. Dial Transplant. 9 Suppl. 2 1994 36 45
40. J.M. Weiler, R.W. Yurt, D.T. Fearon, and K.F. Austen Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin J. Exp. Med. 147 1978 409 421
41. D. Bitter-Suermann, R. Burger, and U. Hadding Activation of the alternative pathway of complement: efficient fluid-phase amplification by blockade of the regulatory complement protein beta1H through sulfated polyanions Eur. J. Immunol. 11 1981 291 295
42. F. Maillet, M.D. Kazatchkine, D. Glotz, E. Fischer, and M. Rowe Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b Mol. Immunol. 20 1983 1401 1404
43. F. Maillet, M. Petitou, J. Choay, and M.D. Kazatchkine Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule Mol. Immunol. 25 1988 917 923